Athira Pharma GAAP EPS of -$0.89 misses by $0.20

Athira Pharma reported a Q3 GAAP EPS of -$0.89, missing estimates by $0.20. The company's cash position decreased to $32.3M as of September 30, 2026, from $88.3M at the end of 2025, with net cash used in operations rising to $18.98M for the quarter, up from $4.7M a year prior.

Original reporting
Published Nov 16, 2026, 9:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 10:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LONA
Bearish
medium confidence
Mentioned
$LONA
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$LONABearishMed
01

Why it matters

A GAAP EPS miss combined with a large reduction in cash and investments can shift expectations toward higher dilution risk or near-term capital needs.

02

Market read

Traders can reassess near-term risk for LONA based on the earnings miss and the reported cash drawdown.

03

What to watch

The excerpt lacks guidance, trial catalysts, and financing plans; traders may overreact without knowing whether the company has runway or upcoming milestones.

Relevance 6/10Novelty 6/10Timing: after-hours/late-day earnings coverage (published 2026-11-16 21:58 UTC)

Background

The piece summarizes Athira Pharma’s Q3 GAAP EPS result and liquidity position as of Sept. 30, 2026.

Company-level read

Ticker impact

$LONABearishMedium confidence
Context

Athira Pharma reported Q3 GAAP EPS of -$0.89, missing by $0.20, alongside a sharp decline in cash versus year-end 2025.

Expected impact

Likely downward pressure as traders price in higher funding risk and weaker operating trajectory.

Evidence & confidence

The article provides the company’s own GAAP EPS miss and a large drop in cash and investments, which typically weighs on micro-cap biotech sentiment and risk appetite.

Market effects

Reinforces broader biotech financing sensitivity to cash burn and GAAP losses, potentially pressuring similar pre-revenue names.

Limited, company-specific impact likely confined to US micro-cap biotech sentiment.

Low, no cross-market policy or macro linkage indicated.

Counterpoint

If the cash decline reflects timing of working-capital movements rather than ongoing burn, the liquidity risk may be overstated.

Key entities

  • Athira Pharma

    US-listed biotech issuer reporting Q3 GAAP EPS and cash position changes.

  • LeonaBio, Inc.

    The article’s byline entity; not the subject of the earnings figures.

Related articles

$LONAMed

In December 2025, as part of a private placement, LeonaBio, Inc. issued warrants to purchase an aggregate of 23,031,494 shares of its common stock

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. In December 2025, as part of a private placement, LeonaBio, Inc. (the “Company”) issued warrants to purchase an aggregate of 23,031,494 shares of its common stock (the “Series A Common Warrants”). The Series A Common Warrants have an exercise price of $6.3

$LONAMed

LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances

LeonaBio (NASDAQ:LONA) reported a Q2 loss of $0.80 per share, smaller than analysts’ $1.12 forecast. Net loss rose to $19.0 million from $7.0 million a year earlier. Phase 3 ELAINE-3 enrollment nears 600 target, with 495 patients enrolled and topline results expected in H2 2027. Cash fell to $51.1 million from $88.3 million.

$DISMedAI 8/10

Disney’s Experiences Segment Hit Record Quarterly Revenue of $10.1 Billion as Cruise Days Surged. Can the Momentum Last?

Disney (DIS) reported Q4 2026 revenue of $25.95B, up 16% YoY, with its Experiences segment hitting a record $10.1B. All units grew, with Experiences leading in operating income at $2.25B. Adjusted net income rose 56% to $3.35B, beating estimates. The company plans to invest $60B in Experiences over a decade, focusing on parks and cruises.